Ocera Therapeutics

Ocera’s lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.

Palo Alto, US
20 (est)+12%

Ocera Therapeutics Locations

Palo Alto, US
Durham, US

Ocera Therapeutics Metrics

Ocera Therapeutics Summary

Founding Date


Market capitalization

$56.8 M

Closing share price


Ocera Therapeutics Market Value History

Ocera Therapeutics News

Ocera Therapeutics Company Life